Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment
Part of paid clinical trials in New York, New York.
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
- Study ID
- NCT01495208
- Phase
- PHASE4
- Status
- Withdrawn
Conditions
- Fibrovascular Pigment Epithelial Detachment
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Aflibercept — DRUGintravitreal aflibercept injection 2mg
Study Details
This is an open label study to evaluate the efficacy of intravitreal aflibercept injection 2mg in patients with a persistent FVPED despite at least 6 consecutive injections with ranibizumab 0.5 mg.
Key Dates
- First listed
- Dec 19, 2011
- Start date
- Dec 31, 2011
- Status verified
- May 2018
- Primary completion
- Oct 31, 2012
- Completion
- Oct 31, 2012
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: aflibercept
Primary Outcome Measure
Change in retinal anatomy (size of FVPED, sub-retinal fluid and retinal volume) from baseline; measured using Spectralis OCT (Heidelberg Engineering, Germany) [ Time Frame: 24 weeks is the primary end point of the study ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Vitreous Retina Macula Consultants of New York | New York | New York | 10022 | - |
Find similar trials in New York, NY
By research site